Cancer Genetics to Report Biomarker Findings in Metastatic Clear Cell Renal Carcinoma Using a CGI-Designed NGS Panel

Cancer Genetics, Inc. CGIX announced the presentation of results from a University of Utah (Huntsman Cancer Institute)-led research study at the 14th International Kidney Cancer Symposium in Miami, Florida, on November 7th, 2015. The study entitled, "Molecular Predictors of Response and Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGFTKIs)" was conducted as a collaboration between Dr. Neeraj Agarwal and CGI. The aim of the study was to investigate molecular markers predictive of response to targeted therapy, to allow better patient selection and guide towards more customized and effective therapy. The HCI and Cancer Genetics teams worked jointly to identify molecular abnormalities or markers in the tumor samples of 89 mccRCC patients treated with targeted therapy. The specimens were subjected to DNA sequencing using a NGS panel designed by CGI specifically for renal cancer and to whole genome array-comparative genomic hybridization. After independent validation, the results of the study will aid in better selection of patients for given treatments, thus minimizing toxicities, managing costs, and facilitating individualized therapy.  See full press release